Evaxion AS (EVAX)

I know Monk, for some reason this is not trading clean.

EVAX, back to 5s

Merck will be interested in partnering, data was very good. the vaccine will be paired with Keytruda in a patented combo. Merck agreed to $600m in milestone payments for an untested vax. with these excellent p2 results, a deal for this vax could be worth $1 billion or more, with more up front cash. real investors will figure this out soon and the stock will rise next week.

EVAX will go down to $5's again, it doesn't look like there are some overhangs, this is purely manipulation by shorts. Volume doesn't suggest anything nefarious by the company and I still believe in the $5's either later today or Monday.

Data was good, people wanted to hear 100% response rate vs 75%.

This has been all over the place last two days. Can't make up its mind.

Damn....back into the 7s data was good?

Wasn't expecting this kind of drop, where are these loose shares coming from? I think you will likely get them in the $5's, I got in at $5.80

Is it rational.to buy here?

EVAX had news today. We should know if it was news worthy, they are keeping a lid on this thing for now, lets see after the open.

understood, ty

Previous post on this thread won't help you much, there are some good ones on Stocktwits, but Yahoo message board is where you want to be to look into this further.

excellent, thank you my friend! going through previous posts now

Through discovery, once the market realizes it's potential with the phase 2 data, this has the potential to hit at least 5 times from here. There is some real good pertinent information on this platform and the science behind it, it is not a flip stock, just needs to be accumulated as funds permit. This is mid to long term hold, yes there will be days you get good spike, but it could surprise the market one day, 600 million from MERCK is not something you sleep on.

Even between 5-7 was a no brainer too. It has plenty of more room to run.

Dinogreeves, is there an even that will take it to the range you discussed earlier - or will it just be through discovery from the market/public?

interested in collecting here and there :)

EVAX will do wonders when it is discovered. Just take a look at PRAX today, the setup is identical with the potential this one has.

Good call anyone who bought at 2-3. Oh well LoL..life

If EVAX data good, that is another $600m vaccine, actually more since it will have passed P3. Let say $1 billion.
Then 'you realize that the EVAX AI platform can keep developing more of them.
Got to be at least 5 $600m-$1 billion market disease targets out there
So a value of $3-6 billion in a buyout eventually achievable.
yes, that is $500-$1000 a share on 6 million shares.

I saw somewhere this could eventually play out to be 500 dollars stock over time if everything pans out.

marvelous rise. the Merck $600m deal for only one vaccine shows how much value the entire platform is worth.
figure minimum $3 billion, maybe double or triple that in a buyout
even after this huge rise, the stock is still ludicrously cheap

EVAX halted up and will boom at the open again north of 18 dollars.

$8.90 ... Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will present a wide range of data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.Click here for full release

EVAX is trucking away to aim for out of reach.

EVAX doing a magnificent move. Getting ready for the next couple of weeks.

Let's pass $7 for good today. Upward.

Evaxion expands AI-Immunology™ platform with automated vaccine design module

New platform module automates previous manual vaccine design processes, improving quality and dramatically reducing time and resource requirements

AI-Immunology™, already superior in vaccine target discovery, now also enables enhanced design applicable for both new vaccines and optimization of approved ones

Evaxion will present detailed validation data on these improvements at the World Vaccine Congress Europe in Amsterdam on October 15, 2025

COPENHAGEN, Denmark, October 8, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is launching a significant improvement of its already leading AI-platform, AI-Immunology™, with a new automated vaccine design module.

Uniquely, the new module automatically provides vaccine designs for maximum protective immune responses by ensuring optional sequence and conformation of the vaccine targets. These targets – or antigens - can already be identified by AI-Immunology™ meaning the platform can now automatically perform the complete process of target discovery and vaccine design.

Automated design can both improve the quality of the vaccines and shorten the design time compared to manual methods from months to days, also carrying significant cost savings. The new module offers solutions for common problems encountered with traditional manual design methods, namely ensuring that vaccine targets can be properly expressed and obtained in the correct conformations. The new design module can be applied to new as well as existing vaccines thereby potentially enabling the development of new and improved generations of vaccines already in use.

Evaxion will present numerous test results confirming the improvement of AI-Immunology™ at the World Vaccine Congress Europe in Amsterdam on October 15, 2025.

shorts throwing in the towel. borrowed shares returned. 60% interest broke them.

shooting up, shorts grip is slipping!

64.625% interest to borrow EVAX on Fidelity

60.375% interest to borrow EVAX on Fidelity

59.875% interest to borrow EVAX on Fidelity

Merck deal worth $600 million. current market cap under $30 million. 20x gain possible?

Merck deal worth $600 million. current market cap under $30 million. 20x gain possible?

EVAX under $2

EVAX under $2

EVAX, under $2

EVAX, under $4

EVAX........................................https://stockcharts.com/h-sc/ui?s=EVAX&p=W&b=5&g=0&id=p86431144783

$4.91 + 100% this round 

EVAX (4-Mil. Flt., 3%): $2.40, 31%; (Open-M) news, $14 target by Wainwright; infect. diseases, cancer, vaccines (Denmark).

yeah, a 1M float will do this. $11pm one day and then down she goes.

Currently $11 😙

EVAX.........................https://stockcharts.com/h-sc/ui?s=EVAX&p=W&b=5&g=0&id=p86431144783

At $4s now $14s not long ago 

$6.02 having a convulsion

evax.....................https://stockcharts.com/h-sc/ui?s=evax&p=W&b=5&g=0&id=p86431144783

PROXY out https://www.otcmarkets.com/filing/html?id=18071025&guid=lKY-kHdxdv3Th3h

Was once a high-flying ticket.

EVAX....................https://stockcharts.com/h-sc/ui?s=EVAX&p=W&b=5&g=0&id=p86431144783